Antisense & RNAi Therapeutics Market Report

Global and Region Antisense & RNAi Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：157
  • REPORT CODE：GMM927734
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Antisense & RNAi Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Antisense & RNAi Therapeuticsmarket, defines the market attractiveness level of Antisense & RNAi Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Antisense & RNAi Therapeutics industry, describes the types of Antisense & RNAi Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Antisense & RNAi Therapeutics market and the development prospects and opportunities of Antisense & RNAi Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Antisense & RNAi Therapeutics market in Chapter 13.

    By Player:

    • Olix Pharmaceuticals

    • Alnylam Pharmaceuticals

    • Ionis Pharmaceuticals

    • Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

    • GlaxoSmithKline Plc

    • Sanofi-Genzyme

    • Benitec Biopharma

    • OncoGeneX Pharmaceuticals

    • Quark Pharmaceuticals

    • miRagen Therapeutics

    • iCo Therapeutics

    • Enzon Pharmaceuticals Inc

    • Rexahn Pharmaceuticals

    • Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

    • Marina Biosciences

    • Gradalis

    • Gene Signal

    • Silence Therapeutics Plc

    • Acuitas Therapeutics

    • Lorus Therapeutics (Aptose Biosciences)

    • Antisense Therapeutics Ltd

    • Bio-Path Holdings Inc

    • Mirna Therapeutics Inc

    By Type:

    • RNA Interference

    • SiRNA

    • MiRNA

    • Antisense RNA

    By End-User:

    • Oncology

    • Cardiovascular

    • Renal

    • Neurodegenerative

    • Respiratory

    • Genetic

    • Infectious Diseases

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Antisense & RNAi Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Antisense & RNAi Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Antisense & RNAi Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Antisense & RNAi Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Antisense & RNAi Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Antisense & RNAi Therapeutics Consumption (2017-2022)

    • 7.2 United States Antisense & RNAi Therapeutics Consumption (2017-2022)

    • 7.3 Europe Antisense & RNAi Therapeutics Consumption (2017-2022)

    • 7.4 China Antisense & RNAi Therapeutics Consumption (2017-2022)

    • 7.5 Japan Antisense & RNAi Therapeutics Consumption (2017-2022)

    • 7.6 India Antisense & RNAi Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Antisense & RNAi Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Antisense & RNAi Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Antisense & RNAi Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Antisense & RNAi Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Antisense & RNAi Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Antisense & RNAi Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Antisense & RNAi Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Antisense & RNAi Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Antisense & RNAi Therapeutics Consumption Forecast (2022-2028)

    9 Global Antisense & RNAi Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Antisense & RNAi Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global RNA Interference Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global SiRNA Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global MiRNA Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Antisense RNA Consumption and Growth Rate (2017-2022)

    • 9.2 Global Antisense & RNAi Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Cardiovascular Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Renal Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Neurodegenerative Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Respiratory Consumption and Growth Rate (2017-2022)

      • 9.2.6 Global Genetic Consumption and Growth Rate (2017-2022)

      • 9.2.7 Global Infectious Diseases Consumption and Growth Rate (2017-2022)

    10 Global Antisense & RNAi Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global RNA Interference Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global SiRNA Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global MiRNA Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Antisense RNA Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Renal Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Neurodegenerative Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Respiratory Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.6 Global Genetic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.7 Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

    11 Global Antisense & RNAi Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Antisense & RNAi Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Antisense & RNAi Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Antisense & RNAi Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Antisense & RNAi Therapeutics Market Competitive Analysis

    • 14.1 Olix Pharmaceuticals

      • 14.1.1 Olix Pharmaceuticals Company Details

      • 14.1.2 Olix Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Olix Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • 14.2 Alnylam Pharmaceuticals

      • 14.2.1 Alnylam Pharmaceuticals Company Details

      • 14.2.2 Alnylam Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Alnylam Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • 14.3 Ionis Pharmaceuticals

      • 14.3.1 Ionis Pharmaceuticals Company Details

      • 14.3.2 Ionis Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • 14.4 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

      • 14.4.1 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) Company Details

      • 14.4.2 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) Antisense & RNAi Therapeutics Product and Service

    • 14.5 GlaxoSmithKline Plc

      • 14.5.1 GlaxoSmithKline Plc Company Details

      • 14.5.2 GlaxoSmithKline Plc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 GlaxoSmithKline Plc Antisense & RNAi Therapeutics Product and Service

    • 14.6 Sanofi-Genzyme

      • 14.6.1 Sanofi-Genzyme Company Details

      • 14.6.2 Sanofi-Genzyme Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Sanofi-Genzyme Antisense & RNAi Therapeutics Product and Service

    • 14.7 Benitec Biopharma

      • 14.7.1 Benitec Biopharma Company Details

      • 14.7.2 Benitec Biopharma Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Benitec Biopharma Antisense & RNAi Therapeutics Product and Service

    • 14.8 OncoGeneX Pharmaceuticals

      • 14.8.1 OncoGeneX Pharmaceuticals Company Details

      • 14.8.2 OncoGeneX Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 OncoGeneX Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • 14.9 Quark Pharmaceuticals

      • 14.9.1 Quark Pharmaceuticals Company Details

      • 14.9.2 Quark Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • 14.10 miRagen Therapeutics

      • 14.10.1 miRagen Therapeutics Company Details

      • 14.10.2 miRagen Therapeutics Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 miRagen Therapeutics Antisense & RNAi Therapeutics Product and Service

    • 14.11 iCo Therapeutics

      • 14.11.1 iCo Therapeutics Company Details

      • 14.11.2 iCo Therapeutics Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 iCo Therapeutics Antisense & RNAi Therapeutics Product and Service

    • 14.12 Enzon Pharmaceuticals Inc

      • 14.12.1 Enzon Pharmaceuticals Inc Company Details

      • 14.12.2 Enzon Pharmaceuticals Inc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Enzon Pharmaceuticals Inc Antisense & RNAi Therapeutics Product and Service

    • 14.13 Rexahn Pharmaceuticals

      • 14.13.1 Rexahn Pharmaceuticals Company Details

      • 14.13.2 Rexahn Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Rexahn Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • 14.14 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

      • 14.14.1 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc) Company Details

      • 14.14.2 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc) Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc) Antisense & RNAi Therapeutics Product and Service

    • 14.15 Marina Biosciences

      • 14.15.1 Marina Biosciences Company Details

      • 14.15.2 Marina Biosciences Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Marina Biosciences Antisense & RNAi Therapeutics Product and Service

    • 14.16 Gradalis

      • 14.16.1 Gradalis Company Details

      • 14.16.2 Gradalis Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Gradalis Antisense & RNAi Therapeutics Product and Service

    • 14.17 Gene Signal

      • 14.17.1 Gene Signal Company Details

      • 14.17.2 Gene Signal Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Gene Signal Antisense & RNAi Therapeutics Product and Service

    • 14.18 Silence Therapeutics Plc

      • 14.18.1 Silence Therapeutics Plc Company Details

      • 14.18.2 Silence Therapeutics Plc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Silence Therapeutics Plc Antisense & RNAi Therapeutics Product and Service

    • 14.19 Acuitas Therapeutics

      • 14.19.1 Acuitas Therapeutics Company Details

      • 14.19.2 Acuitas Therapeutics Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Acuitas Therapeutics Antisense & RNAi Therapeutics Product and Service

    • 14.20 Lorus Therapeutics (Aptose Biosciences)

      • 14.20.1 Lorus Therapeutics (Aptose Biosciences) Company Details

      • 14.20.2 Lorus Therapeutics (Aptose Biosciences) Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Lorus Therapeutics (Aptose Biosciences) Antisense & RNAi Therapeutics Product and Service

    • 14.21 Antisense Therapeutics Ltd

      • 14.21.1 Antisense Therapeutics Ltd Company Details

      • 14.21.2 Antisense Therapeutics Ltd Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Antisense Therapeutics Ltd Antisense & RNAi Therapeutics Product and Service

    • 14.22 Bio-Path Holdings Inc

      • 14.22.1 Bio-Path Holdings Inc Company Details

      • 14.22.2 Bio-Path Holdings Inc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.22.3 Bio-Path Holdings Inc Antisense & RNAi Therapeutics Product and Service

    • 14.23 Mirna Therapeutics Inc

      • 14.23.1 Mirna Therapeutics Inc Company Details

      • 14.23.2 Mirna Therapeutics Inc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.23.3 Mirna Therapeutics Inc Antisense & RNAi Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Antisense & RNAi Therapeutics

    • Figure Antisense & RNAi Therapeutics Picture

    • Table Global Antisense & RNAi Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Antisense & RNAi Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Antisense & RNAi Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Antisense & RNAi Therapeutics Consumption by Country (2017-2022)

    • Figure United States Antisense & RNAi Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Antisense & RNAi Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Antisense & RNAi Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Antisense & RNAi Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Antisense & RNAi Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Antisense & RNAi Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Antisense & RNAi Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Antisense & RNAi Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global RNA Interference Consumption and Growth Rate (2017-2022)

    • Figure Global SiRNA Consumption and Growth Rate (2017-2022)

    • Figure Global MiRNA Consumption and Growth Rate (2017-2022)

    • Figure Global Antisense RNA Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Cardiovascular Consumption and Growth Rate (2017-2022)

    • Figure Global Renal Consumption and Growth Rate (2017-2022)

    • Figure Global Neurodegenerative Consumption and Growth Rate (2017-2022)

    • Figure Global Respiratory Consumption and Growth Rate (2017-2022)

    • Figure Global Genetic Consumption and Growth Rate (2017-2022)

    • Figure Global Infectious Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global RNA Interference Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global SiRNA Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global MiRNA Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Antisense RNA Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Renal Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Neurodegenerative Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Respiratory Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Genetic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Antisense & RNAi Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Antisense & RNAi Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table Olix Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Olix Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Olix Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • Table Alnylam Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Alnylam Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alnylam Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • Table Ionis Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Ionis Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • Table Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) (Foundation Year, Company Profile and etc.)

    • Table Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) Antisense & RNAi Therapeutics Product and Service

    • Table GlaxoSmithKline Plc (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Plc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Plc Antisense & RNAi Therapeutics Product and Service

    • Table Sanofi-Genzyme (Foundation Year, Company Profile and etc.)

    • Table Sanofi-Genzyme Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi-Genzyme Antisense & RNAi Therapeutics Product and Service

    • Table Benitec Biopharma (Foundation Year, Company Profile and etc.)

    • Table Benitec Biopharma Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Benitec Biopharma Antisense & RNAi Therapeutics Product and Service

    • Table OncoGeneX Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table OncoGeneX Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table OncoGeneX Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • Table Quark Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Quark Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Quark Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • Table miRagen Therapeutics (Foundation Year, Company Profile and etc.)

    • Table miRagen Therapeutics Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table miRagen Therapeutics Antisense & RNAi Therapeutics Product and Service

    • Table iCo Therapeutics (Foundation Year, Company Profile and etc.)

    • Table iCo Therapeutics Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table iCo Therapeutics Antisense & RNAi Therapeutics Product and Service

    • Table Enzon Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Enzon Pharmaceuticals Inc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Enzon Pharmaceuticals Inc Antisense & RNAi Therapeutics Product and Service

    • Table Rexahn Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Rexahn Pharmaceuticals Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Rexahn Pharmaceuticals Antisense & RNAi Therapeutics Product and Service

    • Table Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc) (Foundation Year, Company Profile and etc.)

    • Table Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc) Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc) Antisense & RNAi Therapeutics Product and Service

    • Table Marina Biosciences (Foundation Year, Company Profile and etc.)

    • Table Marina Biosciences Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Marina Biosciences Antisense & RNAi Therapeutics Product and Service

    • Table Gradalis (Foundation Year, Company Profile and etc.)

    • Table Gradalis Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gradalis Antisense & RNAi Therapeutics Product and Service

    • Table Gene Signal (Foundation Year, Company Profile and etc.)

    • Table Gene Signal Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gene Signal Antisense & RNAi Therapeutics Product and Service

    • Table Silence Therapeutics Plc (Foundation Year, Company Profile and etc.)

    • Table Silence Therapeutics Plc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Silence Therapeutics Plc Antisense & RNAi Therapeutics Product and Service

    • Table Acuitas Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Acuitas Therapeutics Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Acuitas Therapeutics Antisense & RNAi Therapeutics Product and Service

    • Table Lorus Therapeutics (Aptose Biosciences) (Foundation Year, Company Profile and etc.)

    • Table Lorus Therapeutics (Aptose Biosciences) Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lorus Therapeutics (Aptose Biosciences) Antisense & RNAi Therapeutics Product and Service

    • Table Antisense Therapeutics Ltd (Foundation Year, Company Profile and etc.)

    • Table Antisense Therapeutics Ltd Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Antisense Therapeutics Ltd Antisense & RNAi Therapeutics Product and Service

    • Table Bio-Path Holdings Inc (Foundation Year, Company Profile and etc.)

    • Table Bio-Path Holdings Inc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bio-Path Holdings Inc Antisense & RNAi Therapeutics Product and Service

    • Table Mirna Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Mirna Therapeutics Inc Antisense & RNAi Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mirna Therapeutics Inc Antisense & RNAi Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US